Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
Background: It has been reported that treatment with uracil-tegafur (UFT) has shown significantly better survival and relapse-free survival (RFS) than surgery alone. Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had un...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2009-08, Vol.101 (4), p.598-604 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 604 |
|---|---|
| container_issue | 4 |
| container_start_page | 598 |
| container_title | British journal of cancer |
| container_volume | 101 |
| creator | Park, Y Okamura, K Mitsuyama, S Saito, T Koh, J Kyono, S Higaki, K Ogita, M Asaga, T Inaji, H Komichi, H Kohno, N Yamazaki, K Tanaka, F Ito, T Nishikawa, H Osaki, A Koyama, H Suzuki, T |
| description | Background:
It has been reported that treatment with uracil-tegafur (UFT) has shown significantly better survival and relapse-free survival (RFS) than surgery alone. Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer.
Methods:
A total of 377 node-positive patients with stage I, II, or IIIA disease were registered from September 1996 through July 2000 and were randomly assigned to either 6 cycles of CMF or 2 years of UFT. In both arms, tamoxifen (TAM) was concurrently administered for 2 years. The primary end point in this study was the non-inferiority of UFT to CMF.
Results:
No statistically significant difference between the two groups was observed with regard to the 5-year RFS rate (72.2% in the UFT and 76.3% in the CMF). Adverse event profiles differed between the two groups, with a significantly lower incidence of leukopenia and anaemia in the UFT group, as well as anorexia, nausea/vomiting, stomatitis, and alopecia, which have implications for quality of life.
Conclusion:
UFT administered in combination with TAM holds promise in the treatment of lymph node-positive early breast cancer. On stratified analysis, the recurrence rate in the UFT group was found to be better in oestrogen receptor (ER)-positive patients. Tegafur-based treatment should be evaluated by a prospective randomised trial conducted in ER-positive patients. |
| doi_str_mv | 10.1038/sj.bjc.6605218 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2736822</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826921451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c582t-136ceae32b7e58bf69de5a34dfae118a9efda9ee3afbc03db2ac7a3021aeecd13</originalsourceid><addsrcrecordid>eNp1kk1r3DAQhk1paTZprz0WUWhO640-uracQyGEfhgCvTRnMZbHaxtbciV5yf7J_qYqWZO0gR4kMZpnXo2GN0neMbphVMgL32-qXm-yjG45ky-SFdsKnjLJ85fJilKap7Tg9CQ59b6PYUFl_jo5YUUmZJFnq-T3rQPdDWnAHTSzI2BqEmC0d12Dhuw90Qc92Km1fmph7GpckxFDa4PDOwgxaobZOjs_qKyflXeGTNaH1E7oIHR7JFD38x5MIKGNV9OBNNYRH2CHpFyTMq4Yl2V5RYbDOLXE2BrTqNE9VFcOwQeiwWh0lwSItuMEi7QPc314k7xqYPD4djnPktuvX35ef09vfnwrr69uUr2VPKRMZBoBBa9y3MqqyYoatyA-1Q0gYxIKbOq4oYCm0lTUFQedg6CcAaKumThLPh91p7kasdZogoNBTa4bwR2UhU79mzFdq3Z2r3guMsl5FDhfBJz9NaMPauy8xmEAg3b2ijMqCy5oBD88A_s4bRM_pzgvilxSJiO0OULaWe8dNo-dMKrufaJ8r6JP1OKTWPD-7_6f8MUYEfi4AOA1DI2LM-_8I8dZISST99zFkfMxZXbontr7z9N_AEC13j4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229978018</pqid></control><display><type>article</type><title>Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study</title><source>MEDLINE</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Park, Y ; Okamura, K ; Mitsuyama, S ; Saito, T ; Koh, J ; Kyono, S ; Higaki, K ; Ogita, M ; Asaga, T ; Inaji, H ; Komichi, H ; Kohno, N ; Yamazaki, K ; Tanaka, F ; Ito, T ; Nishikawa, H ; Osaki, A ; Koyama, H ; Suzuki, T</creator><creatorcontrib>Park, Y ; Okamura, K ; Mitsuyama, S ; Saito, T ; Koh, J ; Kyono, S ; Higaki, K ; Ogita, M ; Asaga, T ; Inaji, H ; Komichi, H ; Kohno, N ; Yamazaki, K ; Tanaka, F ; Ito, T ; Nishikawa, H ; Osaki, A ; Koyama, H ; Suzuki, T</creatorcontrib><description>Background:
It has been reported that treatment with uracil-tegafur (UFT) has shown significantly better survival and relapse-free survival (RFS) than surgery alone. Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer.
Methods:
A total of 377 node-positive patients with stage I, II, or IIIA disease were registered from September 1996 through July 2000 and were randomly assigned to either 6 cycles of CMF or 2 years of UFT. In both arms, tamoxifen (TAM) was concurrently administered for 2 years. The primary end point in this study was the non-inferiority of UFT to CMF.
Results:
No statistically significant difference between the two groups was observed with regard to the 5-year RFS rate (72.2% in the UFT and 76.3% in the CMF). Adverse event profiles differed between the two groups, with a significantly lower incidence of leukopenia and anaemia in the UFT group, as well as anorexia, nausea/vomiting, stomatitis, and alopecia, which have implications for quality of life.
Conclusion:
UFT administered in combination with TAM holds promise in the treatment of lymph node-positive early breast cancer. On stratified analysis, the recurrence rate in the UFT group was found to be better in oestrogen receptor (ER)-positive patients. Tegafur-based treatment should be evaluated by a prospective randomised trial conducted in ER-positive patients.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6605218</identifier><identifier>PMID: 19638976</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject><![CDATA[Antineoplastic Agents, Hormonal - administration & dosage ; Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer Research ; Chemotherapy, Adjuvant ; Clinical Study ; Combined Modality Therapy ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Disease-Free Survival ; Drug Resistance ; Epidemiology ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Hematologic and hematopoietic diseases ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphatic Metastasis - pathology ; Mastectomy ; Medical sciences ; Methotrexate - administration & dosage ; Methotrexate - adverse effects ; Middle Aged ; Molecular Medicine ; Neoplasm Staging ; Oncology ; Survival Rate ; Tamoxifen - administration & dosage ; Tamoxifen - adverse effects ; Tegafur - administration & dosage ; Tegafur - adverse effects ; Tumors ; Uracil - administration & dosage ; Uracil - adverse effects]]></subject><ispartof>British journal of cancer, 2009-08, Vol.101 (4), p.598-604</ispartof><rights>The Author(s) 2009</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Aug 18, 2009</rights><rights>Copyright © 2009 Cancer Research UK 2009 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c582t-136ceae32b7e58bf69de5a34dfae118a9efda9ee3afbc03db2ac7a3021aeecd13</citedby><cites>FETCH-LOGICAL-c582t-136ceae32b7e58bf69de5a34dfae118a9efda9ee3afbc03db2ac7a3021aeecd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736822/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736822/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51297,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21938186$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19638976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Y</creatorcontrib><creatorcontrib>Okamura, K</creatorcontrib><creatorcontrib>Mitsuyama, S</creatorcontrib><creatorcontrib>Saito, T</creatorcontrib><creatorcontrib>Koh, J</creatorcontrib><creatorcontrib>Kyono, S</creatorcontrib><creatorcontrib>Higaki, K</creatorcontrib><creatorcontrib>Ogita, M</creatorcontrib><creatorcontrib>Asaga, T</creatorcontrib><creatorcontrib>Inaji, H</creatorcontrib><creatorcontrib>Komichi, H</creatorcontrib><creatorcontrib>Kohno, N</creatorcontrib><creatorcontrib>Yamazaki, K</creatorcontrib><creatorcontrib>Tanaka, F</creatorcontrib><creatorcontrib>Ito, T</creatorcontrib><creatorcontrib>Nishikawa, H</creatorcontrib><creatorcontrib>Osaki, A</creatorcontrib><creatorcontrib>Koyama, H</creatorcontrib><creatorcontrib>Suzuki, T</creatorcontrib><title>Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
It has been reported that treatment with uracil-tegafur (UFT) has shown significantly better survival and relapse-free survival (RFS) than surgery alone. Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer.
Methods:
A total of 377 node-positive patients with stage I, II, or IIIA disease were registered from September 1996 through July 2000 and were randomly assigned to either 6 cycles of CMF or 2 years of UFT. In both arms, tamoxifen (TAM) was concurrently administered for 2 years. The primary end point in this study was the non-inferiority of UFT to CMF.
Results:
No statistically significant difference between the two groups was observed with regard to the 5-year RFS rate (72.2% in the UFT and 76.3% in the CMF). Adverse event profiles differed between the two groups, with a significantly lower incidence of leukopenia and anaemia in the UFT group, as well as anorexia, nausea/vomiting, stomatitis, and alopecia, which have implications for quality of life.
Conclusion:
UFT administered in combination with TAM holds promise in the treatment of lymph node-positive early breast cancer. On stratified analysis, the recurrence rate in the UFT group was found to be better in oestrogen receptor (ER)-positive patients. Tegafur-based treatment should be evaluated by a prospective randomised trial conducted in ER-positive patients.</description><subject>Antineoplastic Agents, Hormonal - administration & dosage</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer Research</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical Study</subject><subject>Combined Modality Therapy</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Disease-Free Survival</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphatic Metastasis - pathology</subject><subject>Mastectomy</subject><subject>Medical sciences</subject><subject>Methotrexate - administration & dosage</subject><subject>Methotrexate - adverse effects</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Survival Rate</subject><subject>Tamoxifen - administration & dosage</subject><subject>Tamoxifen - adverse effects</subject><subject>Tegafur - administration & dosage</subject><subject>Tegafur - adverse effects</subject><subject>Tumors</subject><subject>Uracil - administration & dosage</subject><subject>Uracil - adverse effects</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kk1r3DAQhk1paTZprz0WUWhO640-uracQyGEfhgCvTRnMZbHaxtbciV5yf7J_qYqWZO0gR4kMZpnXo2GN0neMbphVMgL32-qXm-yjG45ky-SFdsKnjLJ85fJilKap7Tg9CQ59b6PYUFl_jo5YUUmZJFnq-T3rQPdDWnAHTSzI2BqEmC0d12Dhuw90Qc92Km1fmph7GpckxFDa4PDOwgxaobZOjs_qKyflXeGTNaH1E7oIHR7JFD38x5MIKGNV9OBNNYRH2CHpFyTMq4Yl2V5RYbDOLXE2BrTqNE9VFcOwQeiwWh0lwSItuMEi7QPc314k7xqYPD4djnPktuvX35ef09vfnwrr69uUr2VPKRMZBoBBa9y3MqqyYoatyA-1Q0gYxIKbOq4oYCm0lTUFQedg6CcAaKumThLPh91p7kasdZogoNBTa4bwR2UhU79mzFdq3Z2r3guMsl5FDhfBJz9NaMPauy8xmEAg3b2ijMqCy5oBD88A_s4bRM_pzgvilxSJiO0OULaWe8dNo-dMKrufaJ8r6JP1OKTWPD-7_6f8MUYEfi4AOA1DI2LM-_8I8dZISST99zFkfMxZXbontr7z9N_AEC13j4</recordid><startdate>20090818</startdate><enddate>20090818</enddate><creator>Park, Y</creator><creator>Okamura, K</creator><creator>Mitsuyama, S</creator><creator>Saito, T</creator><creator>Koh, J</creator><creator>Kyono, S</creator><creator>Higaki, K</creator><creator>Ogita, M</creator><creator>Asaga, T</creator><creator>Inaji, H</creator><creator>Komichi, H</creator><creator>Kohno, N</creator><creator>Yamazaki, K</creator><creator>Tanaka, F</creator><creator>Ito, T</creator><creator>Nishikawa, H</creator><creator>Osaki, A</creator><creator>Koyama, H</creator><creator>Suzuki, T</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>20090818</creationdate><title>Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study</title><author>Park, Y ; Okamura, K ; Mitsuyama, S ; Saito, T ; Koh, J ; Kyono, S ; Higaki, K ; Ogita, M ; Asaga, T ; Inaji, H ; Komichi, H ; Kohno, N ; Yamazaki, K ; Tanaka, F ; Ito, T ; Nishikawa, H ; Osaki, A ; Koyama, H ; Suzuki, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c582t-136ceae32b7e58bf69de5a34dfae118a9efda9ee3afbc03db2ac7a3021aeecd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antineoplastic Agents, Hormonal - administration & dosage</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer Research</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical Study</topic><topic>Combined Modality Therapy</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Disease-Free Survival</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphatic Metastasis - pathology</topic><topic>Mastectomy</topic><topic>Medical sciences</topic><topic>Methotrexate - administration & dosage</topic><topic>Methotrexate - adverse effects</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Survival Rate</topic><topic>Tamoxifen - administration & dosage</topic><topic>Tamoxifen - adverse effects</topic><topic>Tegafur - administration & dosage</topic><topic>Tegafur - adverse effects</topic><topic>Tumors</topic><topic>Uracil - administration & dosage</topic><topic>Uracil - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Y</creatorcontrib><creatorcontrib>Okamura, K</creatorcontrib><creatorcontrib>Mitsuyama, S</creatorcontrib><creatorcontrib>Saito, T</creatorcontrib><creatorcontrib>Koh, J</creatorcontrib><creatorcontrib>Kyono, S</creatorcontrib><creatorcontrib>Higaki, K</creatorcontrib><creatorcontrib>Ogita, M</creatorcontrib><creatorcontrib>Asaga, T</creatorcontrib><creatorcontrib>Inaji, H</creatorcontrib><creatorcontrib>Komichi, H</creatorcontrib><creatorcontrib>Kohno, N</creatorcontrib><creatorcontrib>Yamazaki, K</creatorcontrib><creatorcontrib>Tanaka, F</creatorcontrib><creatorcontrib>Ito, T</creatorcontrib><creatorcontrib>Nishikawa, H</creatorcontrib><creatorcontrib>Osaki, A</creatorcontrib><creatorcontrib>Koyama, H</creatorcontrib><creatorcontrib>Suzuki, T</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Y</au><au>Okamura, K</au><au>Mitsuyama, S</au><au>Saito, T</au><au>Koh, J</au><au>Kyono, S</au><au>Higaki, K</au><au>Ogita, M</au><au>Asaga, T</au><au>Inaji, H</au><au>Komichi, H</au><au>Kohno, N</au><au>Yamazaki, K</au><au>Tanaka, F</au><au>Ito, T</au><au>Nishikawa, H</au><au>Osaki, A</au><au>Koyama, H</au><au>Suzuki, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2009-08-18</date><risdate>2009</risdate><volume>101</volume><issue>4</issue><spage>598</spage><epage>604</epage><pages>598-604</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
It has been reported that treatment with uracil-tegafur (UFT) has shown significantly better survival and relapse-free survival (RFS) than surgery alone. Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer.
Methods:
A total of 377 node-positive patients with stage I, II, or IIIA disease were registered from September 1996 through July 2000 and were randomly assigned to either 6 cycles of CMF or 2 years of UFT. In both arms, tamoxifen (TAM) was concurrently administered for 2 years. The primary end point in this study was the non-inferiority of UFT to CMF.
Results:
No statistically significant difference between the two groups was observed with regard to the 5-year RFS rate (72.2% in the UFT and 76.3% in the CMF). Adverse event profiles differed between the two groups, with a significantly lower incidence of leukopenia and anaemia in the UFT group, as well as anorexia, nausea/vomiting, stomatitis, and alopecia, which have implications for quality of life.
Conclusion:
UFT administered in combination with TAM holds promise in the treatment of lymph node-positive early breast cancer. On stratified analysis, the recurrence rate in the UFT group was found to be better in oestrogen receptor (ER)-positive patients. Tegafur-based treatment should be evaluated by a prospective randomised trial conducted in ER-positive patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19638976</pmid><doi>10.1038/sj.bjc.6605218</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2009-08, Vol.101 (4), p.598-604 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2736822 |
| source | MEDLINE; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer Research Chemotherapy, Adjuvant Clinical Study Combined Modality Therapy Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Disease-Free Survival Drug Resistance Epidemiology Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Hematologic and hematopoietic diseases Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphatic Metastasis - pathology Mastectomy Medical sciences Methotrexate - administration & dosage Methotrexate - adverse effects Middle Aged Molecular Medicine Neoplasm Staging Oncology Survival Rate Tamoxifen - administration & dosage Tamoxifen - adverse effects Tegafur - administration & dosage Tegafur - adverse effects Tumors Uracil - administration & dosage Uracil - adverse effects |
| title | Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A57%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Uracil-tegafur%20and%20tamoxifen%20vs%20cyclophosphamide,%20methotrexate,%20fluorouracil,%20and%20tamoxifen%20in%20post-operative%20adjuvant%20therapy%20for%20stage%20I,%20II,%20or%20IIIA%20lymph%20node-positive%20breast%20cancer:%20a%20comparative%20study&rft.jtitle=British%20journal%20of%20cancer&rft.au=Park,%20Y&rft.date=2009-08-18&rft.volume=101&rft.issue=4&rft.spage=598&rft.epage=604&rft.pages=598-604&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6605218&rft_dat=%3Cproquest_pubme%3E1826921451%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229978018&rft_id=info:pmid/19638976&rfr_iscdi=true |